Biliverdin reductase: More than a namesake-the reductase, its peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C

Frontiers in Pharmacology

Volumn 3 MAR, Issue , 2012, Pages

  Gibbs, Peter E M ^a   Tudor, Cicerone ^b   Maines, Mahin D ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

Biliverdin; Biliverdin reductase; Peptides; Protein kinase C; Signaling pathways

Indexed keywords

AUTOANTIGEN; BILIVERDIN; BILIVERDIN REDUCTASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LYSYLARGINYLASPARAGYLARGINYLTYROSYLLEUCYLSERYLPHENYLALANINE; LYSYLLYSYLARGINYLISOLEUCYLLEUCYLHISTIDYLCYSTEINE; LYSYLTYROSYLCYSTYLCYSTYLSERYLARGINYLLYSINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIDOREDUCTASE; PEPTIDE; PHENYLALANYLGLYCYLPHENYLALANYLPROLYLALANYLPHENYLALANINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C BETA II; PROTEIN KINASE C DELTA; PROTEIN KINASE C XI; PROTEIN TYROSINE KINASE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL PROTECTION; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INDUCTION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

EID: 84865967131     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00031     Document Type: Article

References (66)

1. Ahmad, Z.,Salim, M., and Maines, M. D. (2002). Human biliverdin reductase is a leucine zipper-like DNA-binding protein and functions in transcriptional activation of heme oxygenase1 by oxidative stress. J. Biol. Chem. 277, 9226-9232.
2. Anantharam, V., Kitazawa, M., Wagner, J., Kaul, S., and Kanthasamy, A. G. (2002). Caspase-3-dependent proteolytic cleavage of protein kinase C delta is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. J. Neurosci. 22, 1738-1751.
3. Bharti, A., Kraeft, S. K., Gounder, M., Pandey, P., Jin, S., Yuan, Z. M., Lees-Miller, S. P., Weichselbaum, R., Weaver, D., Chen, L. B., Kufe, D., and Kharbanda, S. (1998). Inactivation of DNA-dependent protein kinase by protein kinase C delta: implications for apoptosis. Mol. Cell. Biol. 18, 6719-6728.
4. Boutros, T., Chevet, E., and Metrakos, P. (2008). Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol. Rev. 60, 261-310.
5. Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., and Siebenlist, U. (1995). Control of I kappa B-alpha proteolysis by site-specific, signalinduced phosphorylation. Science 267, 1485-1488.
6. Buder-Hoffmann, S. A., Shukla, A., Barrett, T. F., Macpherson, M. B., Lounsbury, K. M., and Mossman, B. T. (2009). A protein kinase C delta-dependent protein kinase D pathway modulates ERK1/2 and JNK1/2 phosphorylation and Bimassociated apoptosis by asbestos. Am. J. Pathol. 174, 449-459.
7. Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Basecke, J., Stivala, F., Donia, M., Fagone, P., Malaponte, G., Mazzarino, M. C., Nicoletti, F., Libra, M., Maksimovic-Ivanic, D., Mijatovic, S., Montalto, G., Cervello, M., Laidler, P., Milella, M., Tafuri, A., Bonati, A., Evangelisti, C., Cocco, L., Martelli, A. M., and Mccubrey, J. A. (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2, 135-164.
8. Clark, A. S., West, K. A., Blumberg, P. M., and Dennis, P. A. (2003). Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKC delta promotes cellular survival and chemotherapeutic resistance. Cancer Res. 63, 780-786.
9. Cross, T., Griffiths, G., Deacon, E., Sallis, R., Gough, M., Watters, D., and Lord, J. M. (2000). PKC-delta is an apoptotic lamin kinase. Oncogene 19, 2331-2337.
10. Cutler, R. E. Jr., Maizels, E. T., and Hunzicker-Dunn, M. (1994). Delta protein kinase-C in the rat ovary: estrogen regulation and localization. Endocrinology 135, 1669-1678.
11. Emoto, Y., Manome, Y., Meinhardt, G., Kisaki, H., Kharbanda, S., Robertson, M., Ghayur, T., Wong, W. W., Kamen, R., Weichselbaum, R., and Kufe, D. (1995). Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J. 14, 6148-6156.
12. Gibbs, P. E., and Maines, M. D. (2007). Biliverdin inhibits activation of NFkappaB: reversal of inhibition by human biliverdin reductase. Int. J. Cancer 121, 2567-2574.
13. Gibbs, P. E., Miralem, T., Lerner Marmarosh, N., Tudor, C., and Maines, M. D. (2012). Formation of ternary complex of human biliverdin reductase-protein kinase C delta-ERK2 protein is essential for ERK2-mediated activation of Elk1 protein, nuclear factor-kappaB, and inducible nitric-oxidase synthase (iNOS). J. Biol. Chem. 287, 1066-1079.
14. Gibbs, P. E., Miralem, T., and Maines, M. D. (2010). Characterization of the human biliverdin reductase gene structure and regulatory elements: promoter activity is enhanced by hypoxia and suppressed by TNF{alpha}-activated NF-{kappa}B. FASEB J. 24, 3239-3254.
15. Gorelik, G., Fang, J. Y., Wu, A., Sawalha, A. H., and Richardson, B. (2007). Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J. Immunol. 179, 5553-5563.
16. Granero, F., Revert, F., Revert-Ros, F., Lainez, S., Martinez-Martinez, P., and Saus, J. (2005). A humanspecific TNF-responsive promoter for Goodpasture antigen-binding protein. FEBS J. 272, 5291-5305.
17. Hanks, S. K.,and Hunter, T. (1995). Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9, 576-596.
18. Huang, T. J., Trakshel, G. M., and Maines, M. D. (1989). Detection of 10 variants of biliverdin reductase in rat liver by two-dimensional gel electrophoresis. J. Biol. Chem. 264, 7844-7849.
19. Hudson, B. G., Tryggvason, K., Sundaramoorthy, M., and Neilson, E. G. (2003). Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N.Engl.J.Med.348, 2543-2556.
20. Jackson, D. N., and Foster, D. A. (2004). The enigmatic protein kinase C delta: complex roles in cell proliferation and survival. FASEB J. 18, 627-636.
21. Jacobs, D., Glossip, D., Xing, H., Muslin, A. J., and Kornfeld, K. (1999). Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. Genes Dev. 13, 163-175.
22. Kabu, K., Yamasaki, S., Kamimura, D., Ito, Y., Hasegawa, A., Sato, E., Kitamura, H., Nishida, K., and Hirano, T. (2006). Zinc is required for Fc epsilon RI-mediated mast cell activation. J. Immunol. 177, 1296-1305.
23. Kapitulnik, J., and Maines, M. D. (2009). Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol. Sci. 30, 129-137.
24. Kikuchi, A., Park, S. Y., Miyatake, H., Sun, D., Sato, M., Yoshida, T., and Shiro, Y. (2001). Crystal structure of rat biliverdin reductase. Nat. Struct. Biol. 8, 221-225.
25. Kim, E. K., and Choi, E. J. (2010). Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 1802, 396-405.
26. Kim, H. P., Wang, X., Galbiati, F., Ryter, S. W., and Choi, A. M. (2004). Caveolae compartmentalization of heme oxygenase-1 in endothelial cells. FASEB J. 18, 1080-1089.
27. Kravets, A., Hu, Z., Miralem, T., Torno, M. D., and Maines, M. D. (2004). Biliverdin reductase, a novel regulator for induction of activating transcription factor-2 and heme oxygenase-1. J. Biol. Chem. 279, 19916-19923.
28. Kutty, R. K., and Maines, M. D. (1981). Purification and characterization of biliverdin reductase from rat liver. J. Biol. Chem. 256, 3956-3962.
29. Lerner-Marmarosh, N., Miralem, T., Gibbs, P. E., and Maines, M. D. (2007). Regulation of TNF-alphaactivated PKC-zeta signaling by the human biliverdin reductase: identification of activating and inhibitory domains of the reductase. FASEB J. 21, 3949-3962.
30. Lerner-Marmarosh, N., Miralem, T., Gibbs, P. E., and Maines, M. D. (2008). Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. Proc. Natl. Acad. Sci. U.S.A. 105, 6870-6875.
31. Lerner-Marmarosh, N., Shen, J., Torno, M. D., Kravets, A., Hu, Z., and Maines, M. D. (2005). Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 7109-7114.
32. Litersky, J. M., and Johnson, G. V. (1992). Phosphorylation by cAMPdependent protein kinase inhibits the degradation of tau by calpain. J. Biol. Chem. 267, 1563-1568.
33. Maines, M. D. (2005). New insights into biliverdin reductase functions: linking heme metabolism to cell signaling. Physiology (Bethesda) 20, 382-389.
34. Maines, M. D. (2007). Biliverdin reductase: PKC interaction at the crosstalk of MAPK and PI3K signaling pathways. Antioxid. Redox Signal. 9, 2187-2195.
35. Maines, M. D., Miralem, T., Lerner Marmarosh, N., Shen, J., and Gibbs, P. E. (2007). Human biliverdin reductase, a previously unknown activator of protein kinase C betaII. J. Biol. Chem. 282, 8110-8122.
36. Maines, M. D., Polevoda, B. V., Huang, T. J., and Mccoubrey, W. K. Jr. (1996). Human biliverdin IX alpha reductase is a zinc-metalloprotein. Characterization of purified and Escherichia coli expressed enzymes. Eur. J. Biochem. 235, 372-381.
37. McCracken, M. A., Miraglia, L. J., Mckay, R. A., and Strobl, J. S. (2003). Protein kinase C delta is a prosurvival factor in human breast tumor cell lines. Mol. Cancer Ther. 2, 273-281.
38. Minden, A., and Karin, M. (1997). Regulation and function of the JNK subgroup of MAP kinases. Biochim. Biophys. Acta 1333, F85-F104.
39. Miralem, T., Gibbs, P. E., Revert, F., Saus, J., and Maines, M. D. (2010). Human biliverdin reductase suppresses Goodpasture antigenbinding protein (GPBP) kinase activity: the reductase regulates tumor necrosis factor-alphaNF-kappaB-dependent GPBP expression. J. Biol. Chem. 285, 12551-12558.
40. Miralem, T., Hu, Z., Torno, M. D., Lelli, K. M., and Maines, M. D. (2005). Small interference RNAmediated gene silencing of human biliverdin reductase, but not that of heme oxygenase-1, attenuates arsenite-mediated induction of the oxygenase and increases apoptosis in 293A kidney cells. J. Biol. Chem. 280, 17084-17092.
41. Nabha, S. M., Glaros, S., Hong, M., Lykkesfeldt, A. E., Schiff, R., Osborne, K., and Reddy, K. B. (2005). Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene 24, 3166-3176.
42. Nakao, A., Neto, J. S., Kanno, S., Stolz, D. B., Kimizuka, K., Liu, F., Bach, F. H., Billiar, T. R., Choi, A. M., Otterbein, L. E., and Murase, N. (2005). Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am. J. Transplant. 5, 282-291.
43. Newton, A. C. (2010). Protein kinase C: poised to signal. Am. J. Physiol. Endocrinol. Metab. 298, E395-E402.
44. Osawa, M., Itoh, S., Ohta, S., Huang, Q., Berk, B. C., Marmarosh, N. L., Che, W., Ding, B.,Yan, C., and Abe, J. (2004). ERK1/2 associates with the c-Met-binding domain of growth factor receptor-bound protein 2 (Grb2)-associated binder-1 (Gab1): role in ERK1/2 and early growth response factor-1 (Egr-1) nuclear accumulation. J. Biol. Chem. 279, 29691-29699.
45. Pachori, A. S., Smith, A., Mcdonald, P., Zhang, L., Dzau, V. J., and Melo, L. G. (2007). Heme-oxygenase1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway. J. Mol. Cell. Cardiol. 43, 580-592.
46. Pawson, T., and Scott, J. D. (1997). Signaling through scaffold, anchoring, and adaptor proteins. Science 278, 2075-2080.
47. Quinones, S., Bernal, D., GarciaSogo, M., Elena, S. F., and Saus, J. (1992). Exon/intron structure of the human alpha 3(IV) gene encompassing the Goodpasture antigen (alpha 3(IV)NC1). Identification of a potentially antigenic region at the triple helix/NC1 domain junction. J. Biol. Chem. 267, 19780-19784.
48. Ranganathan, A., Yazicioglu, M. N., and Cobb, M. H. (2006). The nuclear localization of ERK2 occurs by mechanisms both independent of and dependent on energy. J. Biol. Chem. 281, 15645-15652.
49. Raya, A., Revert, F., Navarro, S., and Saus, J. (1999). Characterization of a novel type of serine/threonine kinase that specifically phosphorylates the human goodpasture antigen. J. Biol. Chem. 274, 12642-12649.
50. Revert, F., Merino, R., Monteagudo, C., Macias, J., Peydro, A., Alcacer, J., Muniesa, P., Marquina, R., Blanco, M., Iglesias, M., RevertRos, F., Merino, J., and Saus, J. (2007). Increased Goodpasture antigen-binding protein expression induces type IV collagen disorganization and deposit of immunoglobulin A in glomerular basement membrane. Am. J. Pathol. 171, 1419-1430.
51. Ron, D., Chen, C. H., Caldwell, J., Jamieson, L., Orr, E., and Mochly Rosen, D. (1994). Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. Proc. Natl. Acad. Sci. U.S.A. 91, 839-843.
52. Salim, M., Brown-Kipphut, B. A., and Maines, M. D. (2001). Human biliverdin reductase is autophosphorylated, and phosphorylation is required for bilirubin formation. J. Biol. Chem. 276, 10929-10934.
53. Saus, J. (1998). Goodpasture's Syndrome. London: Academic Press, Ltd.
54. Schlachter, S., Elder, A. D., Esposito, A., Kaminski, G. S., Frank, J. H., Van Geest, L. K., and Kaminski, C. F. (2009). mhFLIM: resolution of heterogeneous fluorescence decays in widefield lifetime microscopy. Opt. Express 17, 1557-1570.
55. Sedlak, T. W., Saleh, M., Higginson, D. S., Paul, B. D., Juluri, K. R., and Snyder, S. H. (2009). Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc. Natl. Acad. Sci. U.S.A. 106, 5171-5176.
56. Srivastava, J., Goris, J., Dilworth, S. M., and Parker, P. J. (2002). Dephosphorylation of PKC delta by protein phosphatase 2Ac and its inhibition by nucleotides. FEBS Lett. 516, 265-269.
57. Steinberg, S. F. (2008). Structural basis of protein kinase C isoform function. Physiol. Rev. 88, 1341-1378.
58. Tanti, J. F., Gremeaux, T., Van Obberghen, E., and Le Marchand Brustel, Y. (1994). Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J. Biol. Chem. 269, 6051-6057.
59. Tudor, C., Lerner-Marmarosh, N., Engelborghs, Y., Gibbs, P. E., and Maines, M. D. (2008). Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. Biochem. J. 413, 405-416.
60. Wegiel, B., Baty, C. J., Gallo, D., Csizmadia, E., Scott, J. R., Akhavan, A., Chin, B. Y., Kaczmarek, E., Alam, J., Bach, F. H., Zuckerbraun, B. S., and Otterbein, L. E. (2009). Cell surface biliverdin reductase mediates biliverdininduced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt. J. Biol. Chem. 284, 21369-21378.
61. Wegiel, B., Gallo, D., Csizmadia, E., Roger, T., Kaczmarek, E., Harris, C., Zuckerbraun, B. S., and Otterbein, L. E. (2011). Biliverdin inhibits Toll-like receptor-4 (TLR4) expression through nitric oxide-dependent nuclear translocation of biliverdin reductase. Proc. Natl. Acad. Sci. U.S.A. 108, 18849-18854.
62. Whitby, F. G., Phillips, J. D., Hill, C. P., Mccoubrey, W., and Maines, M. D. (2002). Crystal structure of a biliverdin IX alpha reductase enzyme-cofactor complex. J. Mol. Biol. 319, 1199-1210.
63. Yamashita, K., Mcdaid, J., Ollinger, R., Tsui, T. Y., Berberat, P. O., Usheva, A., Csizmadia, E., Smith, R. N., Soares, M. P., and Bach, F. H. (2004). Biliverdin,a natural product of heme catabolism, induces tolerance to cardiac allografts. FASEB J. 18,765-767.
64. Yazicioglu, M. N., Goad, D. L., Ranganathan, A., Whitehurst, A. W., Goldsmith, E. J., and Cobb, M. H. (2007). Mutations in ERK2 binding sites affect nuclear entry. J. Biol. Chem. 282, 28759-28767.
65. Yoshida, K., Wang, H. G., Miki, Y., and Kufe, D. (2003). Protein kinase C delta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. EMBO J. 22, 1431-1441.
66. Zhao, J., Renner, O., Wightman, L., Sugden, P. H., Stewart, L., Miller, A. D., Latchman, D. S., and Marber, M. S. (1998). The expression of constitutively active isotypes of protein kinase C to investigate preconditioning. J. Biol. Chem. 273, 23072-23079